Characteristics, mutational profiles and HIV-1 subtype identified in the study population
ID . | HIV-1 pVL (log10 copies/mL) . | Time on RAL (months) . | INI DRMs . | Predicted drug resistance to: . | HIV-1 subtype in IN . | HIV-1 subtype in PR-RT . | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
RAL . | EVG . | DTG . | BIC . | phylogenetic and recombination analysis . | Stanford HIVdb genotyping . | phylogenetic and recombination analysis . | Stanford HIVdb genotyping . | ||||
AR_461008 | 4.92 | 30 | T97A, Y143R | H | L | S | S | B | B | B | B |
AR_470449BIS | 5.54 | 57 | G140S, Q148H | H | H | I | I | B | B | URF_BF | B |
AR_485196 | 5.08 | 14 | L74M, T97A, Y143R, E138K | H | I | L | L | B | B | B | B |
AR_485630 | 5.15 | 27 | Y143R | H | S | S | S | B | B | B | B |
AR_488090 | 4.76 | 8 | G140S, Q148H, E138K | H | H | H | H | B | B | URF_BF | B |
AR_497339 | 4.79 | 11 | G140S, Q148H, E138K | H | H | H | H | B | B | B | B |
AR_5856_AA323RED | 4.73 | 42 | G140S, Q148H | H | H | I | I | B | B | URF_BF | B |
AR_481594 | 4.41 | 21 | T97A, Q148R, E138K, S147G, V151I/V | H | H | H | H | B | B | F | F |
AR_475736 | 2.85 | 23 | L74M, N155H, V151I, G163R | H | H | S | S | F | B | CRF29_BF | CRF29_BF |
AR_477551 | 3.69 | 30 | — | S | S | S | S | F | F | URF_BF | CRF12_BF |
AR_481960 | 4.79 | — | — | S | S | S | S | F | F | CRF12_BF | CRF12_BF |
AR_487095 | 5.31 | 7 | L74I/M, T97A, P142T, G163K | L | L | S | S | F | F | URF_BF | B + F |
AR_490082 | 4.49 | 11 | T97A, Y143R | H | L | S | S | F | F | CRF12_BF | CRF12_BF |
AR_495852 | 4.60 | 42 | L74M, T97A, Y143R | H | I | S | S | F | F | URF_BF | B + F |
AR_598_X785RYL | 4.26 | 36 | G163K | L | L | S | S | F | F | URF_BF | B + F |
AR_497397 | 6.01 | 76 | — | S | S | S | S | F | F | URF_BF | B + F |
AR_5155_T723GM | 6.02 | 12 | L74M, T97A, Y143R | H | I | S | S | F | F | URF_BF | B+F |
AR_4363_W359PMME | 3.68 | 10 | N155N/H | H | H | S | S | F | F | CRF12_BF | CRF12_BF |
AR_3080_AA714DTJL | 3.28 | 28 | T97A, G163R | L | L | S | S | F | F | CRF17_BF | B |
AR_5793_AA770PG | 2.95 | 22 | N155H, G163R | H | H | S | S | F | F | URF_BF | B + F |
AR_2337_AA807FLA | 4.72 | 8 | — | S | S | S | S | F | F | URF_BF | B + F |
AR_3174_AA185BIL | 4.08 | 8 | — | S | S | S | S | F | F | URF_BF | B |
AR_490047 | — | 73 | G140S, Q148H | H | H | I | I | URF_BF | F | URF_BF | B |
AR_3013_W812BDMS | 3.63 | 42 | V151I, N155H | H | H | S | S | URF_BF | B | URF_BF | B |
AR_3302_Y937LLN | 4.52 | 19 | G140S, Q148H | H | H | I | I | URF_BF | B | URF_BF | B |
AR_568_Z708GGA | 4.97 | 27 | G140S, Q148H | H | H | I | I | URF_BF | B | URF_BF | B |
AR_6462_AA893CP | 4.62 | 17 | L74I, G140S, Q148H, E138A | H | H | H | H | URF_BF | F | CRF12_BF | CRF12_BF |
AR_6286_AA416RBBJ | 4.76 | 12 | N155H | H | H | S | S | URF_BF | F | URF_BF | B + F |
AR_3128_Z059UTA | 3.42 | 31 | — | S | S | S | S | URF_BF | F | URF_BF | B |
AR_472584 | 6.62 | 35 | T97A, V151I, N155H | H | H | S | S | ? | CRF05_DF | CRF05_DF | CRF05_DF |
ID . | HIV-1 pVL (log10 copies/mL) . | Time on RAL (months) . | INI DRMs . | Predicted drug resistance to: . | HIV-1 subtype in IN . | HIV-1 subtype in PR-RT . | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
RAL . | EVG . | DTG . | BIC . | phylogenetic and recombination analysis . | Stanford HIVdb genotyping . | phylogenetic and recombination analysis . | Stanford HIVdb genotyping . | ||||
AR_461008 | 4.92 | 30 | T97A, Y143R | H | L | S | S | B | B | B | B |
AR_470449BIS | 5.54 | 57 | G140S, Q148H | H | H | I | I | B | B | URF_BF | B |
AR_485196 | 5.08 | 14 | L74M, T97A, Y143R, E138K | H | I | L | L | B | B | B | B |
AR_485630 | 5.15 | 27 | Y143R | H | S | S | S | B | B | B | B |
AR_488090 | 4.76 | 8 | G140S, Q148H, E138K | H | H | H | H | B | B | URF_BF | B |
AR_497339 | 4.79 | 11 | G140S, Q148H, E138K | H | H | H | H | B | B | B | B |
AR_5856_AA323RED | 4.73 | 42 | G140S, Q148H | H | H | I | I | B | B | URF_BF | B |
AR_481594 | 4.41 | 21 | T97A, Q148R, E138K, S147G, V151I/V | H | H | H | H | B | B | F | F |
AR_475736 | 2.85 | 23 | L74M, N155H, V151I, G163R | H | H | S | S | F | B | CRF29_BF | CRF29_BF |
AR_477551 | 3.69 | 30 | — | S | S | S | S | F | F | URF_BF | CRF12_BF |
AR_481960 | 4.79 | — | — | S | S | S | S | F | F | CRF12_BF | CRF12_BF |
AR_487095 | 5.31 | 7 | L74I/M, T97A, P142T, G163K | L | L | S | S | F | F | URF_BF | B + F |
AR_490082 | 4.49 | 11 | T97A, Y143R | H | L | S | S | F | F | CRF12_BF | CRF12_BF |
AR_495852 | 4.60 | 42 | L74M, T97A, Y143R | H | I | S | S | F | F | URF_BF | B + F |
AR_598_X785RYL | 4.26 | 36 | G163K | L | L | S | S | F | F | URF_BF | B + F |
AR_497397 | 6.01 | 76 | — | S | S | S | S | F | F | URF_BF | B + F |
AR_5155_T723GM | 6.02 | 12 | L74M, T97A, Y143R | H | I | S | S | F | F | URF_BF | B+F |
AR_4363_W359PMME | 3.68 | 10 | N155N/H | H | H | S | S | F | F | CRF12_BF | CRF12_BF |
AR_3080_AA714DTJL | 3.28 | 28 | T97A, G163R | L | L | S | S | F | F | CRF17_BF | B |
AR_5793_AA770PG | 2.95 | 22 | N155H, G163R | H | H | S | S | F | F | URF_BF | B + F |
AR_2337_AA807FLA | 4.72 | 8 | — | S | S | S | S | F | F | URF_BF | B + F |
AR_3174_AA185BIL | 4.08 | 8 | — | S | S | S | S | F | F | URF_BF | B |
AR_490047 | — | 73 | G140S, Q148H | H | H | I | I | URF_BF | F | URF_BF | B |
AR_3013_W812BDMS | 3.63 | 42 | V151I, N155H | H | H | S | S | URF_BF | B | URF_BF | B |
AR_3302_Y937LLN | 4.52 | 19 | G140S, Q148H | H | H | I | I | URF_BF | B | URF_BF | B |
AR_568_Z708GGA | 4.97 | 27 | G140S, Q148H | H | H | I | I | URF_BF | B | URF_BF | B |
AR_6462_AA893CP | 4.62 | 17 | L74I, G140S, Q148H, E138A | H | H | H | H | URF_BF | F | CRF12_BF | CRF12_BF |
AR_6286_AA416RBBJ | 4.76 | 12 | N155H | H | H | S | S | URF_BF | F | URF_BF | B + F |
AR_3128_Z059UTA | 3.42 | 31 | — | S | S | S | S | URF_BF | F | URF_BF | B |
AR_472584 | 6.62 | 35 | T97A, V151I, N155H | H | H | S | S | ? | CRF05_DF | CRF05_DF | CRF05_DF |
Mutations contributing to INI susceptibility according to the Stanford HIVdb program are shown in bold. Mutations known as major are underlined.
pVL, plasma viral load; RAL, raltegravir; EVG, elvitegravir; DTG, dolutegravir; BIC, bictegravir; S, susceptible; H, high-level resistant; I, intermediate-level resistant; L, low-level resistant;—, no mutation detected by Sanger sequencing; ?, could not be confirmed by phylogenetic analysis.
Characteristics, mutational profiles and HIV-1 subtype identified in the study population
ID . | HIV-1 pVL (log10 copies/mL) . | Time on RAL (months) . | INI DRMs . | Predicted drug resistance to: . | HIV-1 subtype in IN . | HIV-1 subtype in PR-RT . | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
RAL . | EVG . | DTG . | BIC . | phylogenetic and recombination analysis . | Stanford HIVdb genotyping . | phylogenetic and recombination analysis . | Stanford HIVdb genotyping . | ||||
AR_461008 | 4.92 | 30 | T97A, Y143R | H | L | S | S | B | B | B | B |
AR_470449BIS | 5.54 | 57 | G140S, Q148H | H | H | I | I | B | B | URF_BF | B |
AR_485196 | 5.08 | 14 | L74M, T97A, Y143R, E138K | H | I | L | L | B | B | B | B |
AR_485630 | 5.15 | 27 | Y143R | H | S | S | S | B | B | B | B |
AR_488090 | 4.76 | 8 | G140S, Q148H, E138K | H | H | H | H | B | B | URF_BF | B |
AR_497339 | 4.79 | 11 | G140S, Q148H, E138K | H | H | H | H | B | B | B | B |
AR_5856_AA323RED | 4.73 | 42 | G140S, Q148H | H | H | I | I | B | B | URF_BF | B |
AR_481594 | 4.41 | 21 | T97A, Q148R, E138K, S147G, V151I/V | H | H | H | H | B | B | F | F |
AR_475736 | 2.85 | 23 | L74M, N155H, V151I, G163R | H | H | S | S | F | B | CRF29_BF | CRF29_BF |
AR_477551 | 3.69 | 30 | — | S | S | S | S | F | F | URF_BF | CRF12_BF |
AR_481960 | 4.79 | — | — | S | S | S | S | F | F | CRF12_BF | CRF12_BF |
AR_487095 | 5.31 | 7 | L74I/M, T97A, P142T, G163K | L | L | S | S | F | F | URF_BF | B + F |
AR_490082 | 4.49 | 11 | T97A, Y143R | H | L | S | S | F | F | CRF12_BF | CRF12_BF |
AR_495852 | 4.60 | 42 | L74M, T97A, Y143R | H | I | S | S | F | F | URF_BF | B + F |
AR_598_X785RYL | 4.26 | 36 | G163K | L | L | S | S | F | F | URF_BF | B + F |
AR_497397 | 6.01 | 76 | — | S | S | S | S | F | F | URF_BF | B + F |
AR_5155_T723GM | 6.02 | 12 | L74M, T97A, Y143R | H | I | S | S | F | F | URF_BF | B+F |
AR_4363_W359PMME | 3.68 | 10 | N155N/H | H | H | S | S | F | F | CRF12_BF | CRF12_BF |
AR_3080_AA714DTJL | 3.28 | 28 | T97A, G163R | L | L | S | S | F | F | CRF17_BF | B |
AR_5793_AA770PG | 2.95 | 22 | N155H, G163R | H | H | S | S | F | F | URF_BF | B + F |
AR_2337_AA807FLA | 4.72 | 8 | — | S | S | S | S | F | F | URF_BF | B + F |
AR_3174_AA185BIL | 4.08 | 8 | — | S | S | S | S | F | F | URF_BF | B |
AR_490047 | — | 73 | G140S, Q148H | H | H | I | I | URF_BF | F | URF_BF | B |
AR_3013_W812BDMS | 3.63 | 42 | V151I, N155H | H | H | S | S | URF_BF | B | URF_BF | B |
AR_3302_Y937LLN | 4.52 | 19 | G140S, Q148H | H | H | I | I | URF_BF | B | URF_BF | B |
AR_568_Z708GGA | 4.97 | 27 | G140S, Q148H | H | H | I | I | URF_BF | B | URF_BF | B |
AR_6462_AA893CP | 4.62 | 17 | L74I, G140S, Q148H, E138A | H | H | H | H | URF_BF | F | CRF12_BF | CRF12_BF |
AR_6286_AA416RBBJ | 4.76 | 12 | N155H | H | H | S | S | URF_BF | F | URF_BF | B + F |
AR_3128_Z059UTA | 3.42 | 31 | — | S | S | S | S | URF_BF | F | URF_BF | B |
AR_472584 | 6.62 | 35 | T97A, V151I, N155H | H | H | S | S | ? | CRF05_DF | CRF05_DF | CRF05_DF |
ID . | HIV-1 pVL (log10 copies/mL) . | Time on RAL (months) . | INI DRMs . | Predicted drug resistance to: . | HIV-1 subtype in IN . | HIV-1 subtype in PR-RT . | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
RAL . | EVG . | DTG . | BIC . | phylogenetic and recombination analysis . | Stanford HIVdb genotyping . | phylogenetic and recombination analysis . | Stanford HIVdb genotyping . | ||||
AR_461008 | 4.92 | 30 | T97A, Y143R | H | L | S | S | B | B | B | B |
AR_470449BIS | 5.54 | 57 | G140S, Q148H | H | H | I | I | B | B | URF_BF | B |
AR_485196 | 5.08 | 14 | L74M, T97A, Y143R, E138K | H | I | L | L | B | B | B | B |
AR_485630 | 5.15 | 27 | Y143R | H | S | S | S | B | B | B | B |
AR_488090 | 4.76 | 8 | G140S, Q148H, E138K | H | H | H | H | B | B | URF_BF | B |
AR_497339 | 4.79 | 11 | G140S, Q148H, E138K | H | H | H | H | B | B | B | B |
AR_5856_AA323RED | 4.73 | 42 | G140S, Q148H | H | H | I | I | B | B | URF_BF | B |
AR_481594 | 4.41 | 21 | T97A, Q148R, E138K, S147G, V151I/V | H | H | H | H | B | B | F | F |
AR_475736 | 2.85 | 23 | L74M, N155H, V151I, G163R | H | H | S | S | F | B | CRF29_BF | CRF29_BF |
AR_477551 | 3.69 | 30 | — | S | S | S | S | F | F | URF_BF | CRF12_BF |
AR_481960 | 4.79 | — | — | S | S | S | S | F | F | CRF12_BF | CRF12_BF |
AR_487095 | 5.31 | 7 | L74I/M, T97A, P142T, G163K | L | L | S | S | F | F | URF_BF | B + F |
AR_490082 | 4.49 | 11 | T97A, Y143R | H | L | S | S | F | F | CRF12_BF | CRF12_BF |
AR_495852 | 4.60 | 42 | L74M, T97A, Y143R | H | I | S | S | F | F | URF_BF | B + F |
AR_598_X785RYL | 4.26 | 36 | G163K | L | L | S | S | F | F | URF_BF | B + F |
AR_497397 | 6.01 | 76 | — | S | S | S | S | F | F | URF_BF | B + F |
AR_5155_T723GM | 6.02 | 12 | L74M, T97A, Y143R | H | I | S | S | F | F | URF_BF | B+F |
AR_4363_W359PMME | 3.68 | 10 | N155N/H | H | H | S | S | F | F | CRF12_BF | CRF12_BF |
AR_3080_AA714DTJL | 3.28 | 28 | T97A, G163R | L | L | S | S | F | F | CRF17_BF | B |
AR_5793_AA770PG | 2.95 | 22 | N155H, G163R | H | H | S | S | F | F | URF_BF | B + F |
AR_2337_AA807FLA | 4.72 | 8 | — | S | S | S | S | F | F | URF_BF | B + F |
AR_3174_AA185BIL | 4.08 | 8 | — | S | S | S | S | F | F | URF_BF | B |
AR_490047 | — | 73 | G140S, Q148H | H | H | I | I | URF_BF | F | URF_BF | B |
AR_3013_W812BDMS | 3.63 | 42 | V151I, N155H | H | H | S | S | URF_BF | B | URF_BF | B |
AR_3302_Y937LLN | 4.52 | 19 | G140S, Q148H | H | H | I | I | URF_BF | B | URF_BF | B |
AR_568_Z708GGA | 4.97 | 27 | G140S, Q148H | H | H | I | I | URF_BF | B | URF_BF | B |
AR_6462_AA893CP | 4.62 | 17 | L74I, G140S, Q148H, E138A | H | H | H | H | URF_BF | F | CRF12_BF | CRF12_BF |
AR_6286_AA416RBBJ | 4.76 | 12 | N155H | H | H | S | S | URF_BF | F | URF_BF | B + F |
AR_3128_Z059UTA | 3.42 | 31 | — | S | S | S | S | URF_BF | F | URF_BF | B |
AR_472584 | 6.62 | 35 | T97A, V151I, N155H | H | H | S | S | ? | CRF05_DF | CRF05_DF | CRF05_DF |
Mutations contributing to INI susceptibility according to the Stanford HIVdb program are shown in bold. Mutations known as major are underlined.
pVL, plasma viral load; RAL, raltegravir; EVG, elvitegravir; DTG, dolutegravir; BIC, bictegravir; S, susceptible; H, high-level resistant; I, intermediate-level resistant; L, low-level resistant;—, no mutation detected by Sanger sequencing; ?, could not be confirmed by phylogenetic analysis.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.